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Fragile X syndrome is the most common form of 
inherited mental retardation, and afflicts 1 in 1250 
males and 1 in 2500 females. The symptoms 
include connective tissue displasia, mental 
retardation, and macroorchidism (enlarged testis). 
My lab discovered that the most common forms of 
this disorder are caused by the expansion of CGG 
tri-nucleotide repeats on the X chromosome at the 
FMR-1 gene locus; an excess of 200 repeats in 
diseased individuals suppresses the translation of 
FMR-1.  The CGG repeat expansion leads to hyper-
methylation of a CpG island distal to the repeat, 
leading to transcriptional repression of FMR-1. This 
gene silencing is also aided by RNA interference 
and de-acetylation of histones H3 and H4. The FMR-
1 gene codes for fragile X mental retardation 
protein (FMRP), which plays a functional role in 
protein translation in neurons. FMRP selectively 
binds to specific mRNAs essential to development 
of the brain and other parts of the body, and plays a 
major role in shuttling its ligands from the 
nucleoplasm to the dendritic cytoplasm. FMRP 
knockout mice models demonstrate abnormal 
dendritic spine growth, suggesting altered synaptic 
plasticity, which may be responsible for the fragile 
X phenotype.  Elucidating the fragile X mechanism 
of pathogenesis can aid the development of 





Fragile X syndrome is one of the most prevalent forms 
of mental retardation affecting approximately 1 in 4,000 
males and 1 in 8,000 females.  FMR1 has been 
identified as the gene associated with fragile X 
syndrome (1, 2, 6).  This gene was mapped revealing a 
CGG tri-nucleotide repeat in the 5’ non-coding region of 
the gene.  This region was noted to expand in repeat 
length in fragile X syndrome (1).  The expansions of the 
CGG repeat to levels of 200 repeats or greater is 
responsible for the instability of the fragile site on the X 
chromosome.  Normal cases posses an average of 30-
50 repeats of the CGG region (27).  This instability 
results in the hypermethylation of a CpG island distal to 
the tri-nucleotide repeat (6,1,26,35).  Examination of 
fragile X patients has consistently shown that the 
hypermethylation of the CpG island is the primary factor 
implementing the fragile X phenotype being that 
methylation is responsible for approximately 99% of 
known fragile X phenotypes (35, 41).  A representation  
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of the FMR1 gene with binding sites and the CpG island 
is depicted in Figure 1.   
 Studies have revealed a significant decrease 
in the expression of FMR1 mRNA in fragile X cases as 
a result of the hypermethylation of the CpG island (35).  
An important feature of repressing of this particular 
gene is the presence of FMR1in fetal tissue.  The 
varying levels of expression between normal and fragile 
X fetal tissue reflects a very important role in 
development.  This data also suggests early acquisition 
of the methylation, probably during embryogenesis 
(38,40). 
 Early acquisition of methylation points out the 
importance of the loss of FMR1 expression.   The 
human FMR1 gene, being highly conserved among 
species (16), has been shown to display alternative 
splicing properties suggesting the presence of many 
isoforms (4).  Mouse models have been developed to 
study fragile X syndrome due to the allelic similarities 
(16).  Three different levels of repeat within the gene 
have been reported: normal (7-50 repeats), permutation 
(50-200 repeats), and full mutation (> 200 repeats).  
The class of permutation is interesting because it only 
becomes affective in successive generations when the 
repeat region has a chance to expand leading to 
Shermans’s paradox.  The permutation allele is 
unstable when transmitted from generation to 
generation.   
All males with the full mutation display the 
fragile X phenotype where only approximately 50% of 
females with the mutation display the fragile X 
phenotype (4, 40).  Taken together with data from our 
more recent studies this proves that the germ line is 
susceptible to full expansion (32).  There seem to be no 
new mutations appearing to cause fragile X syndrome.   
 The only known mutation of resulting in 
fragile X syndrome interestingly shows increases in the 
transcription of FMR1 have been proportionally linked 
to the CGG tri-nucleotide repeat length and the repeat 
number approaches 200 in permutations.  As the 
number of repeats increases the number of FMR1 
mRNA levels increase.  Unexpectedly, the FMR1 
protein products decrease in relation to the CGG repeat 
length in permutation (25).  This finding shows the 
development of the disease at various points of repeat 
length during the permutation stage of fragile X 
syndrome.      
 Upon extending from the permutation to the 
full mutation, the FMR1 gene is silenced.  The silencing 
of the FMR1 gene is interesting because it remains 
unclear as to how the tri-nucleotide repeat expansion 
occurs in an organism.  Moreover, questions still remain 
as to how the loss of the FMR1 protein, FMRP can 
have such broad effects as those observed in fragile X 
syndrome (21, 40).  Studies have started to reveal the 
role and importance of FMRP in patient and mouse 
models uncovering mRNA binding properties (5,29,17)   
Within the past few years we have uncovered 
information linking FMRP to protein synthesis (30) and 
a micro-RNA dependent translational suppression 
pathway (23).  In this review we will focus on explaining 
the neuronal functions and importance of FMRP in 
model systems.  We will also propose a mechanism for 
both translational and transcriptional repression through 




Functions of FMRP                                                                                          
                                                                                       
In fetal tissue, FMRP is found to be most abundantly 
and universally expressed in the testis and the brain 
(21).  The differentiation of neuronal stems cells related 
to the fragile X phenotype has shown alteration in 
fragile X patients linking the disease to development 
(10). FMRP was discovered to assert properties of 
RNA-binding proteins in areas of expression (40).  The 
protein itself encompasses three RNA binding domains, 
two K domains and an RGG box (40, 15).  Importantly, 
the FMRP protein maintains both a nuclear location 
signal (NLS) at the amino terminus end of the FMRP 
and a nuclear export signal (NES) encoded by exon 14 
of the FMRP.  These signals help to confirm RNA 
binding properties of FMRP by hinting at the possible 
translocation of various mRNAs via the FMRP pathway 
(17). 
 In order to bind mRNAs, FMRP forms an 
RNP complex containing FMRP, FRX1P, FRX2P, 
nucleolin, and three other proteins.  The particles 
making up human RNPs are conserved in mice as well. 
(11). This RNP binds mRNA selectively by associating 
the G-quartet structure of the mRNA to the RGG box of 
the FMRP (5, 15).  The G-quartet structure acts as a 
target for FMRP explaining the selective binding 
properties and the importance of transcriptional 
regulation via FMRP of the targeted mRNAs (15).  
FMRP binds directly to mRNAs via this interaction (9).   
 This direct interaction with mRNA allows 
FMRP to act as a translational control factor for many of 
these targeted mRNAs.  Evidence for this was found 
because a large majority of FMRP is associated with 
ribosomes, translational machinery (38).  Because the 
absence of the FMR1 gene was associated with fragile 
X syndrome, a functional role of FMRP was 
investigated (38).  FMRP was found to be associated 
with ribosomes in the dendritic structures of neurons 
elucidating a possible role of the proteins related to 
dendritic structure and neuronal plasticity (18). The 
association of FRMP with polyribosomes was 
eliminated in I304N mutations of extreme fragile X 
syndrome (19).  The tissue specific expression of FMR1 
connects the protein to important developmental 
structures in the brain such as the hippocampus (21).  
A set of FMR1 knockout mouse models were used to 
understand the relationship between drendritic 
formation and FMRP.  Knock out mice were found to 
posses irregular dendritic spines (14).  The importance 
of altered neuronal formation is discussed later. 
 The next important link connecting neuronal 
alterations and the function of FMRP is the evidence 
pointing to negative regulation of mRNA translation.  By 
removing the binding site of FMRP we found a lack of 
translational inhibition (30, 31).  Specifically, FMRP has 
been shown to regulate the production of MAP1B, a 
protein.  In Futsch mutant mice show inverse regulation 
of MAP1B and altered synaptic growth (31, 45).  This 
shows that FMRP possibly plays a major role in 
development of neuronal structure throughout the body. 
 
mRNA ligands associated with FMRP 
 
Because FMRP is shown to play significant roles in 
both mRNA transportation and translation, the 
characteristics of the specific mRNAs associated with 
FMRP have been explored.  A variety of mRNAs are 
associated with FRMP.  One of our recent studies 
examined 13 potential candidate mRNAs associated 
with FMRP and found that at least ten encode proteins 
Figure 1.  Molecular Basis of Fragile X Syndrome: A model of the normal FMR1 gene (top) and the fragile X FMR1 gene (bottom) 
with the defining difference in CCG repeat number between the two labeled.  In the case of repeats >200 (fragile X syndrome), the 
CpG island is hypermethylated, histone 3 and 4  experience changes in acetylation, or RNA interference can all inhibit transcription of 
the FRM1 gene which codes for FMRP.    
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involved in synaptic plasticity or neuronal development.  
This data helped to identify some of the specific mRNA 
translation that is affected in mental retardation (15, 
33).  One specific mRNA was the mRNA coding for 
MAP1B.  MAP1B is negatively regulated in the 
Drosophila nervous system.  In the absence of FMRP, 
MAP1B experiences no inhibition and altered dendrite 
and axon development is noted (45).    
We also interestingly found that FMRP 
associates with the non-translatable BC1 RNA.  In 
addition to binding directly to FMRP, BC1 can associate 
with the FMRP target mRNAs in the absence of FMRP 
(43, 44, 45).  This data suggests that BC1 is involved in 
specificity of FMRP to mRNAs and BC1 helps to inhibit 
translation of some mRNAs by blocking the initiation 
codon (43, 44).  Large numbers of mRNAs have been 
recently associated with FMRP.  Of these mRNAs, 
many have been found to differ in expression and 
distribution among wild type and FMR1 knockout mice 
(31).  These recent studies identifying specific mRNAs 
associated with FMRP and their coded proteins have 
shown the importance of FMRP in neuronal 
development. 
 
Altered neuronal development in Fragile X 
Syndrome 
 
FMRP regulates the translation of many mRNAs which 
code for proteins involved in neuronal development.  
FMRP has been specifically found to be highly 
expressed in neurons.  Areas controlling cognition are 
commonly affected in fragile X syndrome.  A mouse 
model study shows deficient amygdale and 
hippocampal functions in FMR1 knockout mice during 
fear and conditioning tests (36).  Specifically, FMRP is 
highly expressed in the dendritic formations of non-
fragile X organisms (18).  The dendritic functions 
encoded by the target mRNAs of FMRP are deficient in 
fragile X patients thus leading to altered synaptic 
function as observed in the fragile X  phenotype (18). 
 Further proving the neuronal effects of FMR1 
silencing mouse models have elucidated interesting 
findings in the area of altered synaptic plasticity related 
to fragile X mental retardation (22).  Long term 
depression (LTD) dependent on glutamate receptors 
was found to be significantly altered in the 
hippocampus cells of knockout mice.  By using DHPG 
to induce the glutamate dependent LTD, enhanced 
results were found in the knockout mice (22).  This 
supports the earlier hypothesis that FMRP is important 
in regulating protein production in the synapse.    
 In mice lacking the expression of the FMR1 
gene, irregular dendritic spines were observed (26) 
connecting the FMRP protein with synaptic growth.  
Dendritic spines in the visual cortex were compared 
among FMR1 knock out mice and wild type mice to 
explore the specific differences in dendritic growth.  The 
dendrites of the knockout mice show a high incidence 
of long thin dendritic spines as well as dendritic spines 
of higher density (13).  This data combined with the 
mRNAs targeted by FMRP that regulate neuronal 
structure connect fragile X syndrome with altered 
synaptic plasticity. 
FMRP influences synaptic growth by normally 
inhibiting translation of functional mRNAs in 
synaptosomes (18).  Two methods of the release of 
inhibition in normal models have been discovered:  the 
first is dephosphorylation (12) and the second is 
excitation by glutamate receptors (3, 42).  FMRP 
associated with stalled polyribosomes was consistently 
phosphorylated where the FMRP associated with 
actively translating polyribosomes was consistently 
dephorphorylated in both brian cells and cultured cells 
(12).  This is possibly the mechanism by which FMRP 
releases its inhibitory effect on targeted mRNAs.   
Recent models have associated the release 
of translational inhibition with the presence of mRNA 
granules and mGluR-induced translation (3).  FMRP 
normally inhibits mRNA translation, but induction of 
translation has been associated with glutamate 
receptors.  In fragile X syndrome mGluR-induced 
translation is heightened due to the lack of inhibition 
normally provided by FMRP.  The decrease in mRNA 
granules in knockout mice supports this finding.  
Furthermore, upon excitation with an mGluR5 agonist 
increased granule levels were observed (3).  The lack 
of rapid protein translation in sites mediated by 
neurotransmitters such as glutamate has been 
proposed to cause several abnormalities observed in 
fragile X syndrome (41).    
 
The micro-RNA silencing of FMR1 
 
The FMR1 gene is silenced by methylation induced by 
the CGG tri-nucleotide repeat expansion alone, but also 
by interaction with micro-RNAs (23, 24).  FMRP 
interacts with Argonaute  (AGO; 33) and components of 
the micro-RNA pathway such as Dicer (33, 24).  In 
Drosophila melanogaster models the AGO ortholog was 
found to be suppressed in the presence of FMRP.  
When FMRP was removed the models experienced a 
loss of AGO suppression leading to a rough eye 
phenotype.  Upon induced suppression of AGO, the 
rough eye phenotype was significantly reduced to levels 
of almost normal (24).  AGO was found to be important 
to the biological functions of synapses, but not totally 
dependent on FMRP. 
FMRP interacts with many molecules like 
AGO to influence translation.  FMRP also has recently 
been associated with translational regulation through a 
micro-RNA pathway.  Transcripts are produced from 
the expanded fragile X allele at some point early in 
development before complete methylation of the CpG 
island (23, 24, 34).  These transcripts form structures 
referred to as hairpins that are cleaved by the enzyme 
Dicer (23) resulting in small mRNAs approximately 20 
nucleotides in length.  These small mRNAs 
communicate with the RITS complex, a transcriptional 
silencer of genes.  The small RNAs direct the RITS 
complex to homologous mRNAs through 
complementary base pairing.  The RITS complex 
recruits methylation machinery eventually leading to the 
suppression of the FMR1 gene as observed in fragile X 
syndrome (24).  The RITS complex also may change 
the acetylation of specific histones (7, 24). 
 The FMR1 promoting region has shown to 
possess qualities of varying chromatin conformations 
linked to altered histones (20).  When FMR1 is inactive 
as in fragile X cells the chromatin was displayed 
uniform conformation.  In normal cells the interactions 
are far lesser than in fragile X cells (20).  Histones 
acetylation is associated with normally expressed 
FMR1, but not the absence of FMR1 as in fragile X 
syndrome (7, 8, 20).  Recent studies have treated 
fragile X cells with 5-aza-2-deoxycytidine and observed 
re-acetylation of histones 3 and 4.  The re-acetlyation of 
these histones resulted in FMR1 transcriptional 
reactivation (8).  This finding presents an alley of 






FMRP has shown tissue specific expression in areas of 
the brain and other parts of the body associated with 
the observed phenotype of fragile X syndrome such as 
the hippocampus and the testis.  Specific binding of 
FMRP to various mRNAs has been elucidated also 
linking FMRP to an inhibitory role in the translation of 
respective mRNAs.  Translation inhibition and mRNA 
targeting may be influence by non-translatable mRNAs 
such as BC1.  The silencing of the FMR1 gene is the 
central link in fragile X syndrome, however, recent 
studies have shown gene silencing by the binding of 
transcription factors to the promoter regions of FMR1 
(28).  This is data another example of the mechanism 
by which methylation silences the FMR1 gene. 
   The specific mRNAs associated with FMRP 
have proven to reveal a wealth of information explaining 
the gap of knowledge between the silencing of the 
FMR1 gene and the fragile X phenotype.  MAP1B is an 
example of one such mRNA.  MAP1B encodes for 
microtubule structural functions, thereby influencing 
physical features in the development of neurons.  The 
absence of FMRPs regulatory influence leads to 
severely altered neurons in fragile X syndrome.  Figure 
2 proposes an over all view of the FMRP interactions in 
a normal neuron.  
 The alterations observed in fragile X 
syndrome are due to the loss of translational regulation 
via the various pathways that lead to transcriptional 
silencing of FMR1 (methylation of the CpG-island, miro-
RNA interactions, and histone deacetlyation).  Altered 
synaptic plasticity leads to dysfunctional communication 
between neurons.   This altered communication leads 
to the fragile X phenotype observed in humans.   
 The new insights into the AGO (in fly models, 
Drosophila melangaster) and the micro-RNA pathway 
provide insight into a more specific cause of FMR1 
silencing with possible drug treatment options.  The 
mGluR induced translation provides the same exciting 
knowledge about translational regulation and drug 
treatment.  Knowledge pertaining to further functions of 
FMRP still remains elusive along with the cause for the 
CGG tri-nucleotide repeat expansion which is thought 
to be the central cause behind fragile X syndrome.   
 Interesting studies have also shown the 
influence of environmental factors on fragile X 
phenotypes.  When knockout mouse models were 
raised in enriched environments there were found to 
show increased dendrite branching, length, and 
dendrite spine density to levels near normal (39).  This 
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provides non-invasive treatment options to counter the 
silencing of the fragile X gene, FMR1. 
 Transgenic genes have also been explored 
as a possible means of treatment.  Because mouse 
models display some human-like symptoms in 
knockouts, a transgenic line of mice with yeast artificial 
chromosomes were generated.  The study found 
behavioral and morphological changes.  Also, over-
expressing the gene did not have the opposite effect 
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